- Home
- GDTC vs RDI Comparison
GDTC vs RDI Comparison
Compare GDTC & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- RDI
- Stock Information
- Founded
- GDTC 2018
- RDI 1937
- Country
- GDTC Singapore
- RDI United States
- Employees
- GDTC N/A
- RDI N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- GDTC Health Care
- RDI Consumer Discretionary
- Exchange
- GDTC Nasdaq
- RDI Nasdaq
- Market Cap
- GDTC 21.5M
- RDI 27.9M
- IPO Year
- GDTC 2023
- RDI N/A
- Fundamental
- Price
- GDTC $1.89
- RDI $1.30
- Analyst Decision
- GDTC Buy
- RDI
- Analyst Count
- GDTC 1
- RDI 0
- Target Price
- GDTC $5.00
- RDI N/A
- AVG Volume (30 Days)
- GDTC 18.1K
- RDI 26.9K
- Earning Date
- GDTC 01-01-0001
- RDI 08-13-2025
- Dividend Yield
- GDTC N/A
- RDI N/A
- EPS Growth
- GDTC N/A
- RDI N/A
- EPS
- GDTC N/A
- RDI N/A
- Revenue
- GDTC $368,838.00
- RDI $205,644,000.00
- Revenue This Year
- GDTC $5.37
- RDI $7.47
- Revenue Next Year
- GDTC N/A
- RDI $13.22
- P/E Ratio
- GDTC N/A
- RDI N/A
- Revenue Growth
- GDTC N/A
- RDI N/A
- 52 Week Low
- GDTC $1.20
- RDI $1.17
- 52 Week High
- GDTC $4.05
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- GDTC 37.08
- RDI 46.02
- Support Level
- GDTC $1.85
- RDI $1.27
- Resistance Level
- GDTC $1.95
- RDI $1.45
- Average True Range (ATR)
- GDTC 0.10
- RDI 0.06
- MACD
- GDTC -0.02
- RDI 0.00
- Stochastic Oscillator
- GDTC 28.00
- RDI 16.67
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.